BAY-43-9006 Bayer/Onyx

Overview

Journal Curr Opin Investig Drugs

Specialties Infectious Diseases
Pharmacology

Date 2003 Aug 7

PMID 12901237

Citations 13

Authors

John T Lee

James A McCubrey

Affiliations

Soon will be listed here.

Abstract

Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by February 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.

Citing Articles

Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.

Jung H, Bae K, Lee J, Kim J, Han H, Yoon H Int J Mol Sci. 2021; 22(17).

PMID: 34502061 PMC: 8430554. DOI: 10.3390/ijms22179151.

CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment.

Scheiblecker L, Kollmann K, Sexl V Pharmaceuticals (Basel). 2020; 13(12).

PMID: 33255177 PMC: 7760252. DOI: 10.3390/ph13120418.

New landscapes and horizons in hepatocellular carcinoma therapy.

Cervello M, Emma M, Augello G, Cusimano A, Giannitrapani L, Soresi M Aging (Albany NY). 2020; 12(3):3053-3094.

PMID: 32018226 PMC: 7041742. DOI: 10.18632/aging.102777.

Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.

Hirschi B, Gallmeier E, Ziesch A, Marschall M, Kolligs F Mol Cancer. 2014; 13:122.

PMID: 24885690 PMC: 4035728. DOI: 10.1186/1476-4598-13-122.

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.

Dasari A, Gore L, Messersmith W, Diab S, Jimeno A, Weekes C Invest New Drugs. 2012; 31(1):115-25.

PMID: 22415798 DOI: 10.1007/s10637-012-9812-z.